Notably, CD133-targeted CAR-T cells have produced stable disease or partial response in subgroups of patients with pancreatic cancer, whereas CLDN18.2-directed CAR-T cells have shown good disease control rates in gastric, pancreatic, and gastro-esophageal malignancies. The gene discussed is PROM1; the disease is pancreatic neoplasm.